Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jan 16:7:2050313X18823454.
doi: 10.1177/2050313X18823454. eCollection 2019.

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report

Ahmad Haider  1 , Karim Haider  1 , Farid Saad  2   3 , Markolf Hanefeld  4
Affiliations
Case Reports

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report

Ahmad Haider et al. SAGE Open Med Case Rep. .

Abstract

For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile dysfunction. He had type 2 diabetes, was overweight, and had hypertension and dyslipidemia. The blood test revealed testosterone deficiency. Under testosterone therapy, the patient lost 10 kg; cardiometabolic parameters returned to normal and lower urinary tract symptoms disappeared; complete remission of diabetes was recorded. Overweight and obese patients with type 2 diabetes should be tested for hypogonadism and testosterone therapy, if indicated, be considered. These patients can considerably benefit from testosterone therapy in terms of sustainable weight loss and a clinically significant reduction of cardiometabolic risk factors including complete remission of diabetes.

Keywords: Testosterone therapy; cardiometabolic risk factors; obesity; type 2 diabetes; “late-onset” hypogonadism.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.H. has received partial funding for a registry study and travel grants from Bayer AG; K.H. has received travel grants from Bayer AG; F.S. is a full-time employee of Bayer AG.

Figures

Figure 1.
Figure 1.
Testosterone values measured prior to each injection (trough values) returned to the normal range right after the first treatment and remained at that level onward.
Figure 2.
Figure 2.
(a) Significant overweight at baseline was reduced to nearly normal weight within the first 4 years of TTh and weight reduction then maintained onward; (b) a BMI of originally 28.4 kg/m2 was reduced to 25 kg/m2 within the first 4 years of TTh.
Figure 3.
Figure 3.
HbA1c decreased from 7.2% (baseline) to below 6.5% from month 21 onward; fasting blood glucose decreased from 6.6 to 6.0 mmol/L after month 3 and remained below this value onward; HOMA-IR decreased from 8.5 to 2.5 at month 66 (last measurement).
Figure 4.
Figure 4.
(a) The LDL/HDL ratio decreased from 5.4 (baseline) to below 3 from month 30 onward; (b) triglycerides decreased from 3.0 mmol/L (baseline) to below 2.5 mmol/L from month 42 onward.
Figure 5.
Figure 5.
Blood pressure of 176/118 mmHg at baseline normalized to 137/84 mm Hg at month 30.
See this image and copyright information in PMC

References

    1. Astrup A, Finer N. Redefining type 2 diabetes: “diabesity” or “obesity dependent diabetes mellitus”? Obes Rev 2000; 1: 57–59. - PubMed
    1. McCombie L, Leslie W, Taylor R, et al. Beating type 2 diabetes in remission. BMJ 2017; 358: j4030. - PubMed
    1. Chang S, Stoll CRT, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014; 149: 275–287. - PMC - PubMed
    1. Sjöholm K, Pahunen P, Jacobson P, et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia 2015; 58: 1448–1453. - PubMed
    1. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762–769. - PMC - PubMed

Publication types

LinkOut - more resources